Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax Reconfirms Confidence in Regulatory Filing Timelines and Manufacturing Quality
- Statement
- COVID-19
Oct 20, 2021
Novavax Statement on Initial Com-COV2 Phase 2 Clinical Trial Results Presented at World Vaccine Congress Europe
- Statement
- COVID-19
Oct 19, 2021
Novavax to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights on November 4, 2021
- Corporate and Finance
Oct 18, 2021
Novavax to Participate in World Vaccine Congress Europe
- COVID-19
- Seasonal Influenza
Oct 15, 2021
Complete PREVENT-19 Phase 3 Clinical Trial Results Manuscript for COVID-19 Vaccine Posted to medRxiv
- Statement
- COVID-19
Oct 11, 2021
Novavax Announces Leadership Appointment and Updates
- Corporate and Finance
Oct 4, 2021
Novavax to Participate in Health Equity and Vaccine Confidence Panel at Maryland Life Sciences Bio Innovation Conference
- COVID-19
Sep 29, 2021
Novavax Hosts HM King Carl XVI Gustaf and HM Queen Silvia of Sweden During Royal Visit to Uppsala County
- COVID-19
Sep 24, 2021
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
- Seasonal Influenza
Sep 23, 2021
Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine
- COVID-19
Sep 23, 2021
Novavax to Participate in Fireside Chat at the 2021 Cantor Virtual Global Healthcare Conference
- Corporate and Finance
Sep 23, 2021
Novavax to Participate in Fireside Chat at Devex @ UNGA 76
- COVID-19
Sep 20, 2021
Novavax Statement on Proof of COVID-19 Vaccine Requirements for PREVENT-19 Clinical Trial Participants in the U.S.
- Statement
- COVID-19
Sep 17, 2021
Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents
- COVID-19
Sep 16, 2021
Novavax Statement on Takeda Agreement to Provide 150 Million Doses of NVX-CoV2373 to the Government of Japan
- Statement
- COVID-19
Sep 10, 2021
Novavax to Participate in Upcoming September Conferences
- Corporate and Finance
Sep 9, 2021
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
- COVID-19
Sep 8, 2021
Novavax to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
- Corporate and Finance
Sep 7, 2021
Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
- COVID-19
Aug 30, 2021
Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems
- COVID-19
Aug 25, 2021
Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance
- Corporate and Finance
Aug 16, 2021
Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights

Aug 5, 2021
Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
- COVID-19
Aug 5, 2021
Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine
- COVID-19
Aug 5, 2021
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
- COVID-19
Aug 4, 2021

Show per page